Older melanoma patients have better response to immune checkpoint blockade therapy

Source: eCancer, June 2018

Patient age correlates with response to immunotherapy in melanoma and depleting regulatory T cells in young patients may have a therapeutic potential to enhance response in younger patients, according to research from The Wistar Institute.

Study results were published online in Clinical Cancer Research.

Immune checkpoint blockade therapy has been recently approved for treatment of melanoma based on its ability to produce durable disease control.

read the original full article